134 Results for "

MLL

" in MedChemExpress (MCE) Product Catalog:
Products (134)

134 Results for "MLL" in MCE Product Catalog:

17
17 Publications Verification
Cat. No.: HY-136175
CAS No.: 2169919-21-3
Purity:  99.76%
Synonyms: SNDX-5613
Research Areas:  

Cancer

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-16993
CAS No.: 1801787-56-3
Target:  

Apoptosis WDR5

Research Areas:  

Cancer

OICR-9429, a chemical probe, is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-114162
CAS No.: 2169916-18-9
Purity:  99.69%
Synonyms: SNDX-50469
Research Areas:  

Cancer

VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-114162A
CAS No.: 2169919-29-1
Purity:  99.79%
Synonyms: SNDX-50469 fumarate
Research Areas:  

Cancer

VTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 fumarate has potently anti-leukemia activity .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-15650
CAS No.: 1561178-17-3
Purity:  99.68%
Research Areas:  

Cancer

SGC0946 is a selective DOT1L inhibitor with an IC50 value of 0.3 nM. By inhibiting DOT1L, SGC0946 can induce G1 phase arrest, suppress cell self-renewal and metastatic potential, and induce cell differentiation in cancer cells. SGC0946 can be used in the research of tumors such as leukemia and breast cancer, and also serves as a probe to further investigate the cellular mechanisms of DOT1L in normal and diseased cells .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15227
CAS No.: 1338466-77-5
Purity:  99.00%
EPZ004777 is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 can be used for the study of leukemia .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15227A
CAS No.: 1380316-03-9
Purity:  99.46%
EPZ004777 hydrochloride is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 hydrochloride reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 hydrochloride selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 hydrochloride can be used for the study of leukemia .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-16925
CAS No.: 1857417-13-0
Research Areas:  

Cancer

MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12220
CAS No.: 1417329-24-8
Purity:  99.39%
Synonyms: HMTase Inhibitor IX
MM-102 (HMTase Inhibitor IX) is a cell-permeable and tightly binding inhibitor of MLL1-WDR5 interaction (IC50=2.4 nM). MM-102 can specifically inhibit the growth and induce apoptosis of leukemia cells containing MLL1 fusion protein, and reduce renal fibrosis and inflammation in mice with ischemia-reperfusion injury. In addition, MM-102 also acts as an H3K4 histone methyltransferase inhibitor to improve the development of porcine somatic cell nuclear transfer (SCNT) embryos .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-15222
CAS No.: 1271738-62-5
Purity:  99.81%
Research Areas:  

Cancer

Menin-MLL inhibitor MI-2 is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12220A
CAS No.: 1883545-52-5
Purity:  99.68%
Synonyms: HMTase Inhibitor IX TFA
Target:  

WDR5

Research Areas:  

Cancer

MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-19810
CAS No.: 1857417-10-7
Research Areas:  

Cancer

MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-136360
CAS No.: 2134169-43-8
Purity:  98.03%
Research Areas:  

Cancer

MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC50 of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-132001
CAS No.: 2134675-36-6
Purity:  99.13%
Synonyms: KO-539
Research Areas:  

Cancer

Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-148669
CAS No.: 2654081-35-1
Purity:  99.05%
Synonyms: JNJ-75276617; Menin-MLL inhibitor 24
Research Areas:  

Cancer

Bleximenib (JNJ-75276617) is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib can be used in the research of tumors such as leukemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-148669A
CAS No.: 2866179-95-3
Purity:  ≥98.0%
Synonyms: JNJ-75276617 oxalate; Menin-MLL inhibitor 24 oxalate
Research Areas:  

Cancer

Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19809
CAS No.: 1628317-18-9
Research Areas:  

Cancer

MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19347
CAS No.: 890190-22-4
Synonyms: WD-Repeat Protein 5-0103
Target:  

WDR5

Research Areas:  

Neurological Disease Cancer

WDR5-0103 (WD-Repeat Protein 5-0103) is a potent and selective WD repeat-containing protein 5 (WDR5) antagonist with a Kd of 450 nM. WDR5-0103 competitively binds to the peptide-binding pocket of WDR5, blocking the interaction between WDR5 and mixed-lineage leukemia (MLL) protein and inhibiting the methyltransferase activity of MLL. WDR5-0103 is mainly used in the research of cancer and neurodegenerative diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-141429A
CAS No.: 3115178-55-4
Purity:  99.15%
Research Areas:  

Cancer

AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-141429
CAS No.: 2323623-93-2
Research Areas:  

Cancer

AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
loading...
    loading...